James Cook is a member of the Scientific Advisory Board of Molecular Partners, which he joined in 2025. He is currently President of nuclear energy company newcleo Americas and was the Founder of Evergreen Theragnostics, serving as President and Chief Executive Officer prior to its acquisition by Lantheus. Prior to Evergreen, James was General Manager for the U.S. business of Advanced Accelerator Applications (AAA), Senior Director of Strategy at Siemens Healthineers Molecular Imaging (SHMI) and VP Sales and Business Development at PETNET Solutions, a subsidiary of SHMI. James received his MBA from INSEAD in Fontainebleau, France, and Bachelor of Science degrees in Mechanical and Electrical Engineering from Kettering University in Flint, MI.